Exicure (XCUR) Competitors

Exicure (NASDAQ:XCUR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Do analysts rate XCUR or ENTA?

Enanta Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 130.00%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Which has more volatility and risk, XCUR or ENTA?

Exicure has a beta of 3.76, suggesting that its stock price is 276% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Does the media favor XCUR or ENTA?

In the previous week, Enanta Pharmaceuticals had 21 more articles in the media than Exicure. MarketBeat recorded 21 mentions for Enanta Pharmaceuticals and 0 mentions for Exicure. Enanta Pharmaceuticals' average media sentiment score of 0.65 beat Exicure's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Exicure	Neutral
Enanta Pharmaceuticals	Positive

Is XCUR or ENTA more profitable?

Exicure has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -171.57%. Enanta Pharmaceuticals' return on equity of -73.02% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-190.90%	-36.75%
Enanta Pharmaceuticals	-171.57%	-73.02%	-28.70%

Do institutionals and insiders believe in XCUR or ENTA?

42.8% of Exicure shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 3.9% of Exicure shares are held by company insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer XCUR or ENTA?

Enanta Pharmaceuticals received 311 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 57.04% of users gave Enanta Pharmaceuticals an outperform vote while only 47.37% of users gave Exicure an outperform vote.

Company	Underperform	Outperform
Exicure	Outperform Votes 9 47.37%	Underperform Votes 10 52.63%
Enanta Pharmaceuticals	Outperform Votes 320 57.04%	Underperform Votes 241 42.96%

Which has higher valuation and earnings, XCUR or ENTA?

Exicure has higher earnings, but lower revenue than Enanta Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$28.83M	0.91	-$16.91M	-$2.07	-4.87
Enanta Pharmaceuticals	$67.64M	2.37	-$116.04M	-$5.48	-1.37

Summary

Enanta Pharmaceuticals beats Exicure on 15 of the 19 factors compared between the two stocks.